![]() ![]() Andrew Carlson, Neurosurgeon at the University of New Mexico Hospitals in Albuquerque, New Mexico, and Global Coordinating Investigator for the study commented: "Cerebrospinal fluid leakage is one of the most common complications of neurosurgical procedures and a significant burden to patients and healthcare systems. Other registrations are also in progress.ĭr. The Company has seen good uptake, and now, just over a year after the initial launch, LIQOSEAL ® is commercially available throughout Europe via a dedicated network of distribution partners and is registered for use in other countries including Turkey, Israel, Jordan, Argentina. ![]() Polyganics achieved CE mark certification for LIQOSEAL ® in early 2020, based on positive 3-month data from its ENCASE I clinical trial, and immediately launched the device in Europe. Patients will be randomly treated at a 1:1 ratio with either LIQOSEAL ® or an FDA-approved sealant as a control. The trial will involve 228 patients, enrolled and treated at up to 20 clinical centres across the US and Europe. ENCASE II is randomized, two-arm, multicenter study, evaluating the safety and efficacy of LIQOSEAL ® in reducing intra- or post-operative CSF leakage in patients undergoing elective cranial surgery.
0 Comments
Leave a Reply. |